Side-by-side · Research reference

AOD-9604vsMK-677

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2Reviewed10/47 cited

BPhase 2Reviewed13/45 cited

AOD-9604

HGH 176-191 · β3-AR Lipolytic

250–300 mcgDaily doseHeffernan 2001

Phase 2Evidence levelHeffernan 2001 Ng 2008

~30 minHalf-life

SQ · Abdomen · Daily fasted

MK-677

Oral GHS · Ibutamoren

10–25 mgDaily dose (oral)Nass 2008

Phase 2Evidence levelMurphy 1998 Nass 2008

~24 hrHalf-lifeNass 2008

Oral capsule · 1×/day

01Mechanism of Action

Parameter

AOD-9604

MK-677

Primary target

β3-adrenergic receptor (proposed)Ng 2008

Ghrelin receptor (GHS-R1a)Murphy 1998

Pathway

β3-AR activation → cAMP → hormone-sensitive lipase activation → triglyceride breakdown to FFA + glycerolNg 2008

GHS-R1a → Gαq → Ca²⁺ → sustained GH pulses across 24 hrNass 2008

Downstream effect

Lipolysis of adipose tissue triglycerides; FFA release for oxidation; minimal IGF-1 / insulin impactHeffernan 2001

Sustained GH + IGF-1 elevation; appetite stimulation; lean mass preservationNass 2008

Feedback intact?

No GH-axis or IGF-1 feedback

Pulsatile pattern preserved despite long half-lifeMurphy 1998

Origin

Synthetic modified C-terminal hexadecapeptide fragment of human GH (176-191) with N-terminal Tyr substitutionNg 2008

Non-peptide spiroindane-piperidine small molecule designed at MerckMurphy 1998

Antibody development

—

02Dosage Protocols

Parameter

AOD-9604

MK-677

Standard dose

250–300 mcg / dayHeffernan 2001

Anecdotal SQ range. Phase 2 trial dose 1 mg/day oral.

10–25 mg / day oralNass 2008

25 mg used in Nass 2008 elderly trial; 10–15 mg common community dose.

Frequency

Once daily, fasted

Once daily, oral

Lower / starter dose

150 mcg / day

5 mg / day

Evidence basis

Phase 2 trials + animal-strongHeffernan 2001 Ng 2008

Phase 2 trials (Nass 2008, Murphy 1998)Nass 2008 Murphy 1998

Duration

8–12 weeks per cycle

8–16 weeks per cycle (off-cycle to reset receptor sensitivity)

Reconstitution

Bacteriostatic water, 1 mL per 2 mg vial → 2 mg/mL

Oral, no reconstitution

Timing

Morning fasted preferred (pre-cardio)

Aligns with circadian lipolysis.

Pre-sleep preferred for natural GH pulse alignment

Half-life

~30 min plasma

~24 hrNass 2008

Once-daily dosing covers 24 hours.

04Side Effects & Safety

Parameter

AOD-9604

MK-677

Injection site reaction

Mild erythema

—

GI symptoms

Rare mild nausea

—

Cardiovascular

Possible mild HR increase via β3-AR (theoretical β1 cross-reactivity)

No clear adverse signal in trials; congestive heart failure caution

IGF-1 elevation

None — designed to lack GH-axis activityHeffernan 2001

+50–100% sustainedNass 2008

Insulin sensitivity

Neutral — no glucose impairmentHeffernan 2001

—

Cancer risk

No GH/IGF-1 axis activity → lower theoretical risk vs HGH

Contraindicated in active malignancy (GH/IGF-1 axis)

Pregnancy / OB

Avoid

Increased appetite

—

Strong appetite increase via ghrelin agonism

Water retention

—

Mild edema, paresthesias

Glucose tolerance

—

↑ HbA1c +0.3–0.5% in 2-yr elderly trialNass 2008

Drowsiness

—

Common, especially during initial weeks

Absolute Contraindications

AOD-9604

·Pregnancy / breastfeeding
·Severe cardiovascular disease (caution with β-receptor agonists)

MK-677

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis
·Congestive heart failure (caution)

Relative Contraindications

AOD-9604

·Concurrent β-blocker therapy (theoretical antagonism)
·Pheochromocytoma

MK-677

·Untreated diabetes
·Pre-diabetes
·Severe insulin resistance

05Administration Protocol

Parameter

AOD-9604

MK-677

1. Reconstitution

Add 1 mL bacteriostatic water to 2 mg vial → 2 mg/mL = 200 mcg per 0.1 mL.

Capsule or oral solution. No injection.

2. Injection site

SQ — abdomen preferred. Rotate sites.

Oral. Take with or without food.

3. Timing

Morning, fasted, ideally pre-cardio for amplified fat oxidation.

Pre-sleep preferred — aligns with natural GH pulse.

4. Storage

Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.

Capsule: room temp ≤25 °C, dry place.

5. Needle

29–31G, 4–8 mm insulin syringe.

Monitor HbA1c every 8–12 weeks during chronic use.

06Stack Synergy

AOD-9604

+ MOTS-c

Moderate

View MOTS-c →

AOD-9604 mobilises FFAs from adipose via β3-AR; MOTS-c upregulates AMPK / PGC-1α / FAO machinery so that mobilised FFAs are efficiently oxidised. The pathways are sequential — supply (AOD) plus demand (MOTS-c) — and produce more durable lipolytic effects than either alone in anecdotal protocols.

AOD-9604: 250–300 mcg SQ · morning fasted (daily)
MOTS-c: 5 mg SQ · 2–3× per week (pre-workout)
Primary benefit: Fat mobilisation + mitochondrial oxidation, no IGF-1 concern

MK-677

— no documented stacks